Skip to main content
. Author manuscript; available in PMC: 2018 Mar 28.
Published in final edited form as: Compr Physiol. 2016 Dec 6;7(1):1–15. doi: 10.1002/cphy.c160005

Figure 1.

Figure 1

Two eCBs act at CB1 and CB2 receptors with differing affinities and efficacies. AEA, N-arachidonylethanolamine; CB1R, subtype 1 of the cannabinoid receptor; CB2R, subtype 2 of the cannabinoid receptor; 2-AG, 2-arachidonoylglycerol. Affinity refers to the ability of the eCB and receptor to form a bound complex and efficacy refers to the ability of the eCB to induce signaling via the receptor.